Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)

08 Apr 2024 23:10 CEST

Subscribe
Issuer

BIOPHYTIS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1243281_2024_04_08_CP_Programme_OBA_Final.pdf

Source

Biophytis

Provider

Les Echos

Company Name

BIOPHYTIS

ISIN

FR0012816825

Symbol

ALBPS

Market

Euronext Growth

Attachments

  • Original Link
  • Permalink

Disclaimer

Biophytis SA published this content on 08 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 April 2024 21:17:03 UTC.